Studies indicate that genetic factors, including single nucleotide polymorphisms (SNPs), copy number variations (CNVs), HER2 mutations, and HER2 splice variants, might influence treatment effectiveness toward targeted therapies in HER2-positive breast cancer patients or HER2-positive breast cancer cell lines[16-28]. This evidence concerns the gene ERBB2 and breast cancer.